Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma

K. Marumo, Mototsugu Oya, M. Ueno, K. Nakamura, M. Murai, H. Tazaki

Research output: Contribution to journalArticle

Abstract

Eighteen patients with advanced renal cell carcinoma (RCC) were treated with interleukin-2 (IL-2). Seven patients were compared in terms of immunological aspects. They had survived for 55 months or more, and included three patients whose metastatic lesions had disappeared (group A) and 11 patients (group B) who had survived for 1.5 to 39 months. ECOG performance status (PS) was 0 or 1 in six of seven patients in group A, whereas no patient had a PS of 0, three patients had a PS of 1, two patients a PS of 2, and six of the 11 patients in group B had a PS of 3 or 4. Mean natural killer (NK) activity (% 51Cr release) before initiation of the therapy was 50 in group A and 26 in group B patients. However, at 2 weeks and 4 weeks, respectively, after initiation of the therapy, there was no marked difference between the two groups. Lymphokine-activated killer (LAK) activity and the number of peripheral blood lymphocytes before and after initiation of the therapy tended to be higher in group A patients. These results indicated that those patients who had achieved an objective response to IL-2 therapy or survived relatively longer exhibited a better immune status before the initiation of therapy. However, this tendency was not in evidence in some individual patients. Moreover, tumor response to IL-2 therapy was suggested to depend on the sensitivity to killer cells and other biological characteristics of each tumor cell as well as on the immune status of the patients.

Original languageEnglish
Pages (from-to)905-910
Number of pages6
JournalBiotherapy
Volume9
Issue number7
Publication statusPublished - 1995

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Therapeutics
Lymphokines
Neoplasms
Lymphocytes

Keywords

  • Interleukin-2
  • LAK activity
  • NK activity
  • Performance status
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Marumo, K., Oya, M., Ueno, M., Nakamura, K., Murai, M., & Tazaki, H. (1995). Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma. Biotherapy, 9(7), 905-910.

Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma. / Marumo, K.; Oya, Mototsugu; Ueno, M.; Nakamura, K.; Murai, M.; Tazaki, H.

In: Biotherapy, Vol. 9, No. 7, 1995, p. 905-910.

Research output: Contribution to journalArticle

Marumo, K, Oya, M, Ueno, M, Nakamura, K, Murai, M & Tazaki, H 1995, 'Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma', Biotherapy, vol. 9, no. 7, pp. 905-910.
Marumo, K. ; Oya, Mototsugu ; Ueno, M. ; Nakamura, K. ; Murai, M. ; Tazaki, H. / Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma. In: Biotherapy. 1995 ; Vol. 9, No. 7. pp. 905-910.
@article{749993d6b00148e198b4b3881ceca01b,
title = "Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma",
abstract = "Eighteen patients with advanced renal cell carcinoma (RCC) were treated with interleukin-2 (IL-2). Seven patients were compared in terms of immunological aspects. They had survived for 55 months or more, and included three patients whose metastatic lesions had disappeared (group A) and 11 patients (group B) who had survived for 1.5 to 39 months. ECOG performance status (PS) was 0 or 1 in six of seven patients in group A, whereas no patient had a PS of 0, three patients had a PS of 1, two patients a PS of 2, and six of the 11 patients in group B had a PS of 3 or 4. Mean natural killer (NK) activity ({\%} 51Cr release) before initiation of the therapy was 50 in group A and 26 in group B patients. However, at 2 weeks and 4 weeks, respectively, after initiation of the therapy, there was no marked difference between the two groups. Lymphokine-activated killer (LAK) activity and the number of peripheral blood lymphocytes before and after initiation of the therapy tended to be higher in group A patients. These results indicated that those patients who had achieved an objective response to IL-2 therapy or survived relatively longer exhibited a better immune status before the initiation of therapy. However, this tendency was not in evidence in some individual patients. Moreover, tumor response to IL-2 therapy was suggested to depend on the sensitivity to killer cells and other biological characteristics of each tumor cell as well as on the immune status of the patients.",
keywords = "Interleukin-2, LAK activity, NK activity, Performance status, Renal cell carcinoma",
author = "K. Marumo and Mototsugu Oya and M. Ueno and K. Nakamura and M. Murai and H. Tazaki",
year = "1995",
language = "English",
volume = "9",
pages = "905--910",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "7",

}

TY - JOUR

T1 - Host immune reactivity as a prognostic factor in interleukin-2 therapy of renal cell carcinoma

AU - Marumo, K.

AU - Oya, Mototsugu

AU - Ueno, M.

AU - Nakamura, K.

AU - Murai, M.

AU - Tazaki, H.

PY - 1995

Y1 - 1995

N2 - Eighteen patients with advanced renal cell carcinoma (RCC) were treated with interleukin-2 (IL-2). Seven patients were compared in terms of immunological aspects. They had survived for 55 months or more, and included three patients whose metastatic lesions had disappeared (group A) and 11 patients (group B) who had survived for 1.5 to 39 months. ECOG performance status (PS) was 0 or 1 in six of seven patients in group A, whereas no patient had a PS of 0, three patients had a PS of 1, two patients a PS of 2, and six of the 11 patients in group B had a PS of 3 or 4. Mean natural killer (NK) activity (% 51Cr release) before initiation of the therapy was 50 in group A and 26 in group B patients. However, at 2 weeks and 4 weeks, respectively, after initiation of the therapy, there was no marked difference between the two groups. Lymphokine-activated killer (LAK) activity and the number of peripheral blood lymphocytes before and after initiation of the therapy tended to be higher in group A patients. These results indicated that those patients who had achieved an objective response to IL-2 therapy or survived relatively longer exhibited a better immune status before the initiation of therapy. However, this tendency was not in evidence in some individual patients. Moreover, tumor response to IL-2 therapy was suggested to depend on the sensitivity to killer cells and other biological characteristics of each tumor cell as well as on the immune status of the patients.

AB - Eighteen patients with advanced renal cell carcinoma (RCC) were treated with interleukin-2 (IL-2). Seven patients were compared in terms of immunological aspects. They had survived for 55 months or more, and included three patients whose metastatic lesions had disappeared (group A) and 11 patients (group B) who had survived for 1.5 to 39 months. ECOG performance status (PS) was 0 or 1 in six of seven patients in group A, whereas no patient had a PS of 0, three patients had a PS of 1, two patients a PS of 2, and six of the 11 patients in group B had a PS of 3 or 4. Mean natural killer (NK) activity (% 51Cr release) before initiation of the therapy was 50 in group A and 26 in group B patients. However, at 2 weeks and 4 weeks, respectively, after initiation of the therapy, there was no marked difference between the two groups. Lymphokine-activated killer (LAK) activity and the number of peripheral blood lymphocytes before and after initiation of the therapy tended to be higher in group A patients. These results indicated that those patients who had achieved an objective response to IL-2 therapy or survived relatively longer exhibited a better immune status before the initiation of therapy. However, this tendency was not in evidence in some individual patients. Moreover, tumor response to IL-2 therapy was suggested to depend on the sensitivity to killer cells and other biological characteristics of each tumor cell as well as on the immune status of the patients.

KW - Interleukin-2

KW - LAK activity

KW - NK activity

KW - Performance status

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0029047388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029047388&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029047388

VL - 9

SP - 905

EP - 910

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 7

ER -